• Dec5

    Requests for this Liquid Biopsy NGS Panel are Soaring

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Liquid biopsy is an increasingly hot topic in oncology today and is rapidly emerging as an important tool for precision medicine… The term “liquid biopsy” refers to the minimally invasive sampling and molecular analysis of body liquids, primarily blood, as a diagnostic and monitoring tool for diseases such as cancer. It is a simple alternative […]

    » Continue Reading

  • Nov21

    One of CGI’s Most Powerful Tools in Our Immuno-Oncology Portfolio: Multiplex Gene Expression Across 770 Genes

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    At CGI, we adopt a technology- and platform-agnostic approach to our biopharma service portfolio. It enables us to offer a wide range of fit-for-purpose services, specifically-tailored to our clients’ overall scientific and clinical objectives. Continually adding to our comprehensive menu of clinically-validated diagnostic tests, and making strategic investments into cutting-edge technologies are keys to our […]

    » Continue Reading

  • Nov14

    CGI NGS Panel Changes the Paradigm for Multiple Myeloma

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Focus::Myeloma™ replaces the multi-faceted, multi-modality complexity of current multiple myeloma diagnostics to one NGS assay, eliminating need for multiple tests while providing more accurate, timely, and cost-effective prognostic insights Focus::Myeloma™ is CGI’s state-of-the-art, CLIA-validated disease-specific NGS test that enables deeper, more detailed evaluation of multiple myeloma (MM) patients for routine clinical management and clinical trials. The test […]

    » Continue Reading

  • Nov7

    AntigenID™ – CGI’s Neoantigen Discovery Service

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Advancing the Development of Personalized and Targeted Immune Therapies Early last week, we issued a press release formally announcing the launch of our neoantigen discovery service: AntigenID™. This unique and comprehensive offering enables the surveying of existing and discovery of novel neoantigens to accelerate the development of personalized cancer immuno-oncology (IO) therapies while guiding treatment response […]

    » Continue Reading

  • Nov2

    CGI Drives New Testing Paradigm for Lung Cancer with the FDA-Approved Oncomine Dx Target Test

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    CGI is one of the first labs and precision medicine companies to offer Thermo Fisher’s 23-Gene Universal CDx Test CGI has the honor of being part of Thermo Fisher’s Next Generation Sequencing (NGS) Center of Excellence Program (COEP). As a preferred partner, CGI helps Thermo Fisher develop and commercialize NGS-based companion diagnostic (CDx) testing solutions […]

    » Continue Reading

  • Oct10

    On May 25th, These Biomarkers Became Famous…(and They’ve Been on CGI’s Test Menu for Over 5 Years)

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    FDA’s approval of Keytruda (pembrolizumab) on May 25th was an important first for the cancer community – the first time the agency had approved a drug to be given based on biomarkers of patients’ tumors, rather than the location in the body or the tumor type. Merck’s checkpoint inhibitor was approved for patients with solid […]

    » Continue Reading

  • Aug29

    Cancer Genetics Acquires vivoPharm, Enhancing its Value Proposition for Oncology Discovery and Development

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    “We are delighted vivoPharm’s unique value proposition of integrated preclinical, safety and biomarker profiling, both in-vitro and in-vivo, have combined with Cancer Genetics and a team at the forefront of precision oncology.” Ralf Brandt, PhD New President of CGI Discovery & Early Development Services . . Cancer Genetics, Inc. (Nasdaq: CGIX) announced on August 14th […]

    » Continue Reading

  • Aug8

    CGI Named as Thermo Fisher Companion Diagnostic Center of Excellence

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    “Thermo Fisher is committed to expanding its strategic alliances with organizations that share our vision of developing advanced technologies that help doctors get their patients on the right treatment quickly.”  Joydeep Goswami, PhD, MBA, President of Clinical Next Generation Sequencing and Oncology At CGI, we act with urgency to make the biggest impact of precision oncology […]

    » Continue Reading

  • Jul25

    Frost & Sullivan Honors CGI with the 2017 North American Technology Innovation Award in Precision Oncology

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Read full Frost & Sullivan report >> “…CGI’s recent launches of cutting edge tests, its ability to partner with innovative companies, and its extensive research collaborations with leading academic institutions and cancer centers are a testament to the value and depth of CGI’s commitment to driving industry innovation… The company constantly strives for diversity and […]

    » Continue Reading

  • Jul10

    CGI’s Role in the First FDA-Approved Companion Diagnostic Next Generation Sequencing Test

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    CGI is One of the First Laboratories in the USA to Offer the 23-Gene Universal CDx Test Thermo Fisher’s Oncomine™ Dx Target Test is the first targeted next generation sequencing (NGS) Companion Diagnostic (CDx) for non-small cell lung cancer (NSCLC) that simultaneously screens tumors samples for multiple biomarkers for a number of NSCLC targeted therapies […]

    » Continue Reading

  • Jun20

    Accelerating Precision Oncology with Artificial Intelligence

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Artificial Intelligence is creating many opportunities for transformative disruption across the entire oncology value chain – from drug discovery to patient monitoring. And, CGI is leading the charge… Artificial Intelligence – or AI – has evolved into an umbrella term of sorts to refer to the broad set of techniques and methods to train computers […]

    » Continue Reading

  • May30

    Focus::Lymphoma™ | Comprehensive, Clinically Actionable, and Disease-Specific Proprietary NGS

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    It’s been a year since the launch of our CLIA-validated proprietary Focus::Lymphoma™ panel.  To date, it remains the most comprehensive and clinically actionable disease-specific lymphoma panel in precision medicine. Since its introduction into the clinical trial setting in early 2016, Focus::Lymphoma™ has been utilized to power academic studies and several clinical trials, as well as […]

    » Continue Reading

  • May23

    Cleveland Clinic Top 10 Medical Innovations for 2017 | Liquid Biopsy: #4

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Liquid biopsies are able to provide information equal to or superior to traditional invasive tumor sampling procedures. With the increased recognition of the power of liquid biopsy technologies, it is no surprise there is an exploding hope, interest, and commitment in the liquid biopsy area. Cleveland clinic has ranked Liquid Biopsy as #4 on its […]

    » Continue Reading

  • May10

    CGI Selected by Scientist.com for Supplier Spotlight

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Scientist.com has selected Cancer Genetics, Inc. (CGI; Nasdaq: CGIX) to be featured for this month’s Supplier Spotlight. Scientist.com (formerly Assay Depot) is the largest online marketplace for scientific and pharmaceutical research services connecting thousands of researchers to service providers.  Scientist.com saves its users time, reduces costs, improves access to innovation, and ensures compliance. Recently, the […]

    » Continue Reading

  • May8

    The New Paradigm for Lung Cancer Diagnosis & Monitoring

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Liquid::Lung-cfDNA™ CGI Launches a Clinically Actionable, Multi-Gene, Liquid Biopsy Test for Lung Cancer Patients The “liquid biopsy” is making cancer diagnosis and treatment monitoring more efficient, precise, and convenient for patients. In fact, it’s rapidly becoming part of the new standard of care. And, CGI is taking active steps in leveraging high-performance, high-impact liquid biopsy […]

    » Continue Reading

  • Apr26

    Complete::IO™ – CGI’s New Panel to Advance Immuno-Oncology and Precision Therapy

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    As you may have seen, Cancer Genetics, Inc. (CGI; Nasdaq: CGIX) issued a press release earlier this week announcing our Complete::IO™ flow cytometry panel.   This unique and comprehensive panel enables informed therapeutic decisions and assessment of potential toxicities for novel immuno-oncology (IO) therapies across both blood cancers and solid tumors. Immune-modulating agents, both non-specific (bacillus […]

    » Continue Reading

  • Apr6

    CGI Adopts the Avoca Diligent Prequalification Platform to Help Sponsors in the Clinical Trial Vendor Selection Process

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    As an oncology diagnostic and clinical trial service provider, CGI recently became an early adopter of the innovative Avoca Diligent Prequalification Platform by The Avoca Group. THE ADDED VALUE OF AVOCA DILIGENT PREQUALIFICATION PLATFORM Increase quality, Improve efficiency, Reduce risk, and Accelerate the selection of critical clinical trial service providers Recently, the Avoca Group invited […]

    » Continue Reading

  • Mar20

    CGI’s Response to the Genomics Gap in Renal Cancer Drug Development

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    Focus::Renal™ – The Most Comprehensive Molecular Profiling Tool for Kidney Cancer Clinical Testing & Clinical Trial Testing The presentation, “Genomics of RCC” at the 3rd Annual Summit on Genitourinary Malignancies in NYC in October 2016 was by an internationally recognized leader in the area of genitourinary cancers Sumanta (Monty) Kumar Pal, MD.  Dr. Pal presented […]

    » Continue Reading

  • Mar2

    CGI’s Comprehensive Approach to Liquid Biopsy

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    TECHNOLOGY AGNOSTIC LIQUID BIOPSY SOLUTIONS As liquid biopsies have become an area of intense research, commercial activity, and a reality in cancer treatment, Cancer Genetics, Inc. (CGI; Nasdaq: CGIX) has actively taken steps to continue at the forefront in cancer diagnostics by evaluating and qualifying liquid biopsy tests for a broad range of indications. Liquid […]

    » Continue Reading

  • Feb17

    Going to Tri-Con Next Week?

    Written by: Anna Israyelyan, MD, PhD , Manager, Biopharma Solutions

    Anna Israyelyan, MD, PhD

    If you are part of the diagnostics and drug discovery ecosystem, the Tri-Conference ranks as one of the must attend events of the year. The week-long event is scheduled to kick off this Sunday, February 19th, in beautiful San Francisco. With a 24 year history of delivering molecular medicine and diagnostics breakthroughs and technologies, the […]

    » Continue Reading